

FH FLAGLER RESEARCH REPORT TO THE COMMUNITY 2017

Research = Hope. Everything that we know about cancer and current cancer treatments, we have learned from the patients who came before us who participated in cancer clinical trials.

The purpose of cancer clinical trials is to find safer and more effective ways to prevent, diagnose or treat cancer. Based on the results of some of those past studies, we now find ourselves living in a very exciting time for cancer research!

In our past research reports to the community, we discussed dramatic developments in immunotherapy and “personalized” cancer treatments with genetic sequencing. Those exciting developments are ongoing, and we continue to build on what we have learned.

In 2017, FH Flagler and our Florida Cancer Specialists/Sarah Cannon Network collaboration (at FHMMC/FCS Daytona Center) enabled us to provide 31 clinical trials for patients with multiple disease sites.

FH Flagler Medical and Radiation Oncologists, Surgeons, Nurse Navigators, Social Workers and the Cancer Research Office at FHMMC/FCS worked together as a team to inform patients about our trials and to facilitate participation in them for those patients who were interested.

In addition to those trials, FH Flagler also participated in the **ACR Lung Cancer Screening Registry** which significantly added to our accrual.

Based on analytic case numbers of 485, our total research accrual rate was **16%**. This exceeds the national average of adults enrolled on to cancer clinical trials (**3 to 5%**). This also exceeds Commission on Cancer Research goal for accreditation which is **2%**.

We are excited to announce two new breast cancer trials at our FHMMC/Daytona Cancer Site that FH Flagler patients will be eligible for referral for. The first is a trial using a novel agent for metastatic triple negative breast cancer which showed impressive data at the recent San Antonio Breast Cancer Symposium. **BRE 298 # (IMMU-132-05)**: An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic (Stage IV) Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments NCT02574455.

We are also excited about the first adjuvant breast cancer trial through FCS which is: **BRE 294** - A phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, high risk early breast cancer NCT03078751

In 2018, we will be able to offer many new clinical trials to those affected with cancer in our community. Our trial menu changes monthly, so please contact us if you are interested in finding out more about clinical trials.

Until we have a 100% cure, we need clinical trials. Research is Hope. One day we **WILL** cure cancer.

FH Flagler Clinical Trial Accrual Rate of Analytic Cancer Cases

